Market Closed -
Bombay S.E.
11:00:48 09/05/2024 BST
|
5-day change
|
1st Jan Change
|
116.2
INR
|
-1.02%
|
|
-5.95%
|
+2.06%
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
18,753
|
17,634
|
18,981
|
58,952
|
33,033
|
18,037
|
Enterprise Value (EV)
1 |
21,293
|
20,177
|
21,812
|
61,119
|
36,092
|
22,056
|
P/E ratio
|
4.45
x
|
36.1
x
|
27.3
x
|
62.6
x
|
81.1
x
|
-14.9
x
|
Yield
|
0.26%
|
0.28%
|
-
|
0.21%
|
-
|
-
|
Capitalization / Revenue
|
2.21
x
|
1.7
x
|
1.61
x
|
4.33
x
|
2.34
x
|
1.27
x
|
EV / Revenue
|
2.51
x
|
1.94
x
|
1.85
x
|
4.49
x
|
2.55
x
|
1.55
x
|
EV / EBITDA
|
24.4
x
|
15.5
x
|
13.1
x
|
29.2
x
|
36.5
x
|
70.8
x
|
EV / FCF
|
-58.8
x
|
49.3
x
|
63.3
x
|
80.4
x
|
-859
x
|
-39
x
|
FCF Yield
|
-1.7%
|
2.03%
|
1.58%
|
1.24%
|
-0.12%
|
-2.56%
|
Price to Book
|
2.9
x
|
2.47
x
|
2.55
x
|
8.17
x
|
4.78
x
|
2.58
x
|
Nbr of stocks (in thousands)
|
242,291
|
245,426
|
244,289
|
244,717
|
246,880
|
248,471
|
Reference price
2 |
77.40
|
71.85
|
77.70
|
240.9
|
133.8
|
72.59
|
Announcement Date
|
09/08/18
|
05/08/19
|
03/08/20
|
30/08/21
|
29/08/22
|
08/08/23
|
Fiscal Period: März |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
8,478
|
10,393
|
11,792
|
13,616
|
14,128
|
14,209
|
EBITDA
1 |
871
|
1,299
|
1,661
|
2,092
|
987.6
|
311.6
|
EBIT
1 |
457.6
|
907.5
|
1,252
|
1,688
|
584.2
|
-153.5
|
Operating Margin
|
5.4%
|
8.73%
|
10.62%
|
12.39%
|
4.13%
|
-1.08%
|
Earnings before Tax (EBT)
1 |
236.4
|
588.8
|
940.8
|
1,366
|
533.9
|
-1,377
|
Net income
1 |
4,216
|
486.6
|
699
|
954.4
|
412.5
|
-1,212
|
Net margin
|
49.72%
|
4.68%
|
5.93%
|
7.01%
|
2.92%
|
-8.53%
|
EPS
2 |
17.40
|
1.990
|
2.850
|
3.850
|
1.650
|
-4.880
|
Free Cash Flow
1 |
-362.2
|
409.2
|
344.7
|
760.6
|
-42
|
-565.5
|
FCF margin
|
-4.27%
|
3.94%
|
2.92%
|
5.59%
|
-0.3%
|
-3.98%
|
FCF Conversion (EBITDA)
|
-
|
31.51%
|
20.76%
|
36.36%
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
84.09%
|
49.32%
|
79.69%
|
-
|
-
|
Dividend per Share
2 |
0.2000
|
0.2000
|
-
|
0.5000
|
-
|
-
|
Announcement Date
|
09/08/18
|
05/08/19
|
03/08/20
|
30/08/21
|
29/08/22
|
08/08/23
|
Fiscal Period: March |
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
---|
Net sales
1 |
-
|
3,506
|
3,580
|
3,837
|
EBITDA
1 |
-
|
196.8
|
362.2
|
333.5
|
EBIT
|
-
|
-
|
-
|
-
|
Operating Margin
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
Net income
|
8.73
|
-
|
171.2
|
-
|
Net margin
|
-
|
-
|
4.78%
|
-
|
EPS
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
Announcement Date
|
10/08/21
|
01/11/21
|
11/02/22
|
26/05/22
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
2,540
|
2,543
|
2,831
|
2,167
|
3,060
|
4,020
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
2.916
x
|
1.958
x
|
1.705
x
|
1.036
x
|
3.098
x
|
12.9
x
|
Free Cash Flow
1 |
-362
|
409
|
345
|
761
|
-42
|
-565
|
ROE (net income / shareholders' equity)
|
1.21%
|
7.95%
|
10.7%
|
13.9%
|
5.94%
|
-16.4%
|
ROA (Net income/ Total Assets)
|
1.76%
|
4.15%
|
5.39%
|
7.39%
|
2.58%
|
-0.64%
|
Assets
1 |
239,349
|
11,713
|
12,978
|
12,918
|
16,010
|
188,252
|
Book Value Per Share
2 |
26.70
|
29.10
|
30.50
|
29.50
|
28.00
|
28.10
|
Cash Flow per Share
2 |
1.630
|
2.790
|
2.800
|
2.180
|
2.320
|
1.670
|
Capex
1 |
470
|
254
|
407
|
528
|
325
|
862
|
Capex / Sales
|
5.55%
|
2.45%
|
3.45%
|
3.88%
|
2.3%
|
6.07%
|
Announcement Date
|
09/08/18
|
05/08/19
|
03/08/20
|
30/08/21
|
29/08/22
|
08/08/23
|
|
1st Jan change
|
Capi.
|
---|
| +2.06% | 350M | | +32.36% | 698B | | +26.51% | 568B | | -4.40% | 358B | | +19.46% | 328B | | +3.50% | 283B | | +16.34% | 238B | | +6.68% | 203B | | -9.08% | 198B | | +8.62% | 165B |
Other Pharmaceuticals
|